Payment overview · 2025
General Payments
$389.34
21 reported records · 10 companies
Healthcare provider profile · identity verified
Deborah Lynn Eisenmann, MD
Allopathic & Osteopathic Physicians|Family Medicine · MT PLEASANT, MI · NPI 1235227950
Verified facts
What the public records show
CMS Open Payments records show Deborah Lynn Eisenmann, MD received $389.34 in general payments during 2025 across 21 reported records.
Janssen Pharmaceuticals, Inc accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $144.20 | 37.0% | 7 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $56.35 | 14.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.95 | 8.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.86 | 8.7% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $32.34 | 8.3% | 2 | 2025 |
| bioMerieux Inc | Unresolved — no canonical attribution shown | $22.00 | 5.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $19.27 | 5.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.65 | 4.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.46 | 4.0% | 1 | 2025 |
| Visby Medical, Inc. | Unresolved — no canonical attribution shown | $13.26 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $389.34 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $127.39 | 6 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $56.35 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $32.34 | 2 | 2025 |
Source payment records
|
|||||
| BIOFIRE SPOTFIRE Control Station Normalized: biofire spotfire control station |
Device | bioMerieux Inc | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| Visby Medical Sexual Health Click Test Normalized: visby medical sexual health click test |
Device | Visby Medical, Inc. | $13.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 94 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 68 | 11 |
| Omeprazole | Omeprazole | 68 | suppressed |
| Spironolactone | Spironolactone | 57 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | suppressed |
| Losartan Potassium | Losartan Potassium | 49 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 11 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 36 | suppressed |
| Metformin Hcl | Metformin Hcl | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 33 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Gabapentin | Gabapentin | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Salsalate | Salsalate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $389.34 · 21 records | Janssen Pharmaceuticals, Inc | ABRYSVO, Auvelity, BIOFIRE SPOTFIRE Control Station, BRIXADI, COMIRNATY, INVEGA SUSTENNA, Leqembi, Omnipod, PREVNAR 20, SPRAVATO, SUBLOCADE, The Cologuard Plus Collection Kit, Visby Medical Sexual Health Click Test | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error